Dr. Porsteinsson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
601 Elmwood Ave
# 320
Rochester, NY 14642Phone+1 585-275-6733- Is this information wrong?
Summary
- Anton P. Porsteinsson is Director of the University of Rochester Alzheimer’s Disease Care, Research and Education Program (AD-CARE) in New York, USA. In addition, he is the inaugural William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine at the University of Rochester School of Medicine and Dentistry.
Dr. Porsteinsson has devoted his career to the care and study of individuals with memory disorders. He participates in the University of Rochester Memory Care Program, which serves a population with memory disorders. Internationally recognized in clinical research and considered one of the leading experts in Alzheimer’s disease and dementia, he has research interests in biomarkers, imaging, and novel pharmacological agents in the treatment of Alzheimer’s disease and other dementias, both in terms of cognitive loss and behavioral disturbances. He is a leading investigator for several prominent national and international Alzheimer’s disease prevention and treatment trials. He also sits on and chairs multiple Data Safety Monitoring Boards.
Dr. Porsteinsson is the author and collaborator of hundreds of research publications and serves as site principal investigator for multiple research grants from the National Institutes of Health and other leading funders.
Education & Training
- University of RochesterResidency, Psychiatry, 1989 - 1993
- University of IcelandClass of 1987
Certifications & Licensure
- NY State Medical License 1996 - 2026
- WI State Medical License 1991 - 1999
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Citalopram for Agitation in Alzheimer's Disease Start of enrollment: 2009 Jul 01
- The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) Start of enrollment: 2014 Jan 08
- Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Start of enrollment: 2014 Feb 28
Publications & Presentations
PubMed
- Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study.Emily D Clark, Jamie Perin, Nathan Herrmann, Olga Brawman-Mintzer, Krista L Lanctôt, Alan J Lerner, Jacobo Mintzer, Prasad R Padala, Paul B Rosenberg, Susie Sami, Davi...> ;Alzheimer's & Dementia. 2023 Aug 2
- 1 citationsHeterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial.Krista L Lanctôt, Luc Rivet, Shankar Tumati, Jamie Perin, Krushnaa Sankhe, Danielle Vieira, Jacobo Mintzer, Paul B Rosenberg, David Shade, Alan J Lerner, Prasad R Pada...> ;The American Journal of Geriatric Psychiatry. 2023 Dec 1
- Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).Krista L Lanctôt, Clara Chen, Ethan Mah, Alex Kiss, Abby Li, Dave Shade, Roberta W Scherer, Danielle Vieira, Hamadou Coulibaly, Paul B Rosenberg, Alan J Lerner, Prasad...> ;International Psychogeriatrics. 2023 Nov 1
- Join now to see all
Press Mentions
- New Insights on Treating Neurodegeneretive Diseases Could Lead to New Classes of Clinical Trials for Alzheimer’s DiseaseMarch 21st, 2023
- FDA Approves Leqembi, New Treatment for Early-Stage Alzheimer’s DiseaseJanuary 9th, 2023
- Local Adults Involved in 'Game-Changing' Alzheimer's Drug TrialSeptember 30th, 2022
- Join now to see all
Grant Support
- Depression In Alzheimer'S Disease Study 2 (Diads-2)National Institute Of Mental Health2003–2007
Hospital Affiliations
- Strong Memorial Hospital of the University of RochesterRochester, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: